A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

Summary

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Cyclophosphamide

  Days 1, 8 and 15, Cycles 1-8

• Drug
  Bortezomib

  Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+

• Drug
  Dexamethasone

  Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8

• Drug
  Daratumumab

  Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+

Locations (11)